Direct Dose Conversion: Azstarys to Adderall XR 30mg
There is no established direct dose equivalence between Azstarys (serdexmethylphenidate/dexmethylphenidate) and Adderall XR (mixed amphetamine salts) because these are fundamentally different stimulant classes—methylphenidate-based versus amphetamine-based medications. The FDA label for Azstarys explicitly states not to substitute it for other methylphenidate products on a milligram-per-milligram basis, and this principle extends even more strongly to cross-class conversions 1.
Why Direct Conversion Is Not Possible
Methylphenidate and amphetamine have different mechanisms of action, potency ratios, and individual patient responses. While both block monoamine reuptake, their relative effects on dopamine versus norepinephrine differ, and approximately 70% of patients respond to either methylphenidate or amphetamine alone, but nearly 90% respond when both are tried—indicating these are not interchangeable medications 2.
Practical Approach When Switching
When transitioning from Adderall XR 30mg to Azstarys, discontinue the amphetamine and initiate Azstarys using standard titration protocols rather than attempting dose equivalence 1.
Starting Dose Strategy:
- For patients 13-17 years or adults: Start Azstarys 39.2/7.8 mg once daily in the morning
- For patients 6-12 years: Start Azstarys 39.2/7.8 mg once daily (can decrease to 26.1/5.2 mg if needed)
- After one week, increase to 52.3/10.4 mg daily based on response and tolerability (maximum dose) 1
Rationale for This Approach:
The middle starting dose (39.2/7.8 mg) is appropriate because:
- Adderall XR 30mg represents a moderate-to-high amphetamine dose
- The patient has demonstrated tolerance to stimulant therapy
- This allows upward or downward titration based on individual response
The combined molar dose in Azstarys 39.2/7.8 mg is equivalent to 30 mg dexmethylphenidate hydrochloride (25.9 mg dexmethylphenidate free base) 1. However, this does NOT mean it equals Adderall XR 30mg—it simply describes the methylphenidate content.
Critical Monitoring During Transition
Monitor closely during the first 1-2 weeks for:
- Symptom control: Use standardized ADHD rating scales from patients/parents/teachers 2
- Adverse effects: Particularly appetite suppression, insomnia, irritability, cardiovascular effects 1
- Breakthrough symptoms: May indicate need for dose adjustment
Important Caveats
Individual response variability is substantial. Some patients may require the maximum Azstarys dose (52.3/10.4 mg) to achieve symptom control comparable to Adderall XR 30mg, while others may need less 1. The pharmacokinetic profile differs significantly—Azstarys provides rapid onset with extended 13-hour duration 3, whereas Adderall XR has its own distinct release profile.
If adequate symptom control is not achieved after appropriate titration over one month, consider switching back to amphetamine-based therapy or trying alternative medications 1. The historical guideline data suggests that when one stimulant class fails, switching to the other class (methylphenidate ↔ amphetamine) is appropriate 2.